Immunovant, Inc.
IMVT · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,590,400 | $4,365,341 | $1,908,898 | $604,333 |
| - Cash | $713,971 | $635,365 | $376,532 | $493,817 |
| + Debt | $98 | $138 | $1,220 | $2,364 |
| Enterprise Value | $1,876,527 | $3,730,114 | $1,533,586 | $112,880 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$437,775 | -$269,978 | -$208,083 | -$155,907 |
| % Margin | – | – | – | – |
| Net Income | -$413,840 | -$259,336 | -$210,960 | -$156,730 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.73 | -1.88 | -1.71 | -1.43 |
| % Growth | -45.2% | -9.9% | -19.6% | – |
| Operating Cash Flow | -$375,874 | -$214,227 | -$188,193 | -$106,112 |
| Capital Expenditures | -$759 | -$360 | -$197 | -$254 |
| Free Cash Flow | -$376,633 | -$214,587 | -$188,390 | -$106,366 |